Author(s) :
Vlad Mihai Croitoru1, Diana Bogdan1*, Ioana Mihaela Dinu1, Monica Ionela Miron1, Irina Mihaela Cazacu1, Ioana Niculina Luca1, Iulia Gramaticu1, Florina Buica1,2, Adina Emilia Croitoru1,2
1Department of Oncology, Fundeni Clinical Institute
2 Faculty of Medicine, “Titu Maiorescu” University Bucharest, Romania
Corresponding author: Diana Bogdan, Email: diana_bogdan@yahoo.ro
Publication History: Received - , Revised - , Accepted - , Published Online - .
Copyright: © The author(s). Published by Casa Cărții de Știință.
User License: Creative Commons Attribution – NonCommercial (CC BY-NC)
PDF
Share
Valoarea DOI extrasă din ACF este: 10.53011/JMRO.2021.01.06
Număr de citări pe Crossref pentru DOI 10.53011/JMRO.2021.01.06: 0
Verifică manual răspunsul API la acest link: http://api.crossref.org/works/10.53011/JMRO.2021.01.06
Abstract
Neuroendocrine lung tumors are rare neoplasms, with an increasing incidence in the last thirty years. Metastatic disease is rarely curable. We present the case of a 65-year-old male patient with atypical functional carcinoid of the lung and synchronous liver metastases beginning with carcinoid syndrome treated with somatostatin analogues, chemotherapy, and peptide receptor radionuclide therapy, with a good clinical response and remission of the carcinoid syndrome.
